About Boryung Pharmaceutical
Boryung Pharmaceutical is a company based in Seoul (South Korea) founded in 1963. The company has 1,650 employees as of December 31, 2024. Boryung Pharmaceutical has completed 1 acquisition, including ViGenCell. Boryung Pharmaceutical offers products and services including Pharmaceutical Products and Investor Relations Services.
- Headquarter Seoul, South Korea
- Employees 1650 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Boryung Corporation
-
Annual Revenue
$691.63 M (USD)18.32as on Dec 31, 2024
-
Net Profit
$47.21 M (USD)73.2as on Dec 31, 2024
-
EBITDA
$76.84 M (USD)1.09as on Dec 31, 2024
-
Latest Funding Round
Not available
-
Investors
Not available
-
Employee Count
1650
as on Dec 31, 2024
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Boryung Pharmaceutical
Boryung Pharmaceutical is a publicly listed company on the KRX with ticker symbol 003850 in South Korea, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Boryung Pharmaceutical
Boryung Pharmaceutical offers a comprehensive portfolio of products and services, including Pharmaceutical Products and Investor Relations Services.
Pharmaceutical drugs and related items are offered by the company in the healthcare sector.
Information on company history and missions is provided to investors through designated platforms.
Funding Insights of Boryung Pharmaceutical
Detailed funding history for Boryung Pharmaceutical
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Boryung Pharmaceutical
Boryung Pharmaceutical has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include ViGenCell.
Investment portfolio details for Boryung Pharmaceutical
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
T-cell therapies for tumor treatment are developed by ViGenCell.
|
Locked | Locked | 2013 | Locked |
Complete acquisition details for Boryung Pharmaceutical
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Boryung Pharmaceutical
Detailed financials for Boryung Pharmaceutical
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Boryung Pharmaceutical Comparisons
Peer comparison for Boryung Pharmaceutical
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Boryung Pharmaceutical
Detailed competitors of Boryung Pharmaceutical
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Boryung Pharmaceutical
Complete news archive for Boryung Pharmaceutical
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Boryung Pharmaceutical
Boryung Pharmaceutical was founded in 1963.
Boryung Pharmaceutical is headquartered in Seoul, South Korea.
Tae Choi is the current CEO of Boryung Pharmaceutical.
As of Dec 31, 2024, the latest employee count at Boryung Pharmaceutical is 1,650.
Annual revenue of Boryung Pharmaceutical is $691.63M as on Dec 31, 2024.
Boryung Pharmaceutical was established in 1963 and is headquartered in Seoul, South Korea. Operations focus on the pharmaceutical sector, where active pharmaceutical ingredients (APIs) and finished formulations are produced for multiple disease categories. Development activities span various therapeutic areas, supporting drug manufacturing and distribution primarily within the Asian market. Leadership is provided by CEO Tae Choi, overseeing core research and production processes.
Boryung Pharmaceutical offers Pharmaceutical Products and Investor Relations Services.
Yes, Boryung Pharmaceutical is publicly traded on KRX under the ticker symbol 003850.
Boryung Pharmaceutical has made 1 acquisition, including ViGenCell.
The ticker symbol of Boryung Pharmaceutical is 003850 on KRX.